ADIL - Adial Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.2646
-0.0035 (-1.31%)
At close: 03:58PM EDT
0.2749 +0.01 (+3.89%)
After hours: 04:58PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
MACD

MACD

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.2681
Open0.2500
Bid0.2643 x 1100
Ask0.2920 x 1100
Day's Range0.2500 - 0.2799
52 Week Range0.2000 - 2.0800
Volume113,878
Avg. Volume280,774
Market Cap8.261M
Beta (5Y Monthly)0.95
PE Ratio (TTM)N/A
EPS (TTM)-0.4500
Earnings DateAug 14, 2023 - Aug 18, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ADIL

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Adial Pharmaceuticals to Present at the 2023 Jefferies Global Healthcare Conference on June 9th

    CHARLOTTESVILLE, Va., June 01, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced today that it will be presenting at the Jefferies 2023 Global Healthcare Conference being held June 7-9, 2023, at the Marriott Marquis in New York, NY. Cary Claiborne, Chief Executive Officer of Adial Pharmaceuti

  • GlobeNewswire

    Adial Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

    Conducted meetings with U.S. and select European regulatory agencies Received Notice of Exercise and upfront cash of $0.45 million from Advocate for the sale of Purnovate assets and business Ended 2023 first quarter with cash and cash equivalents of $2.3 million CHARLOTTESVILLE, Va., May 12, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevent

  • GlobeNewswire

    Adial Pharmaceuticals Receives Notice of Exercise from Adovate for the Acquisition of Purnovate’s Assets and Business

    Adial to receive potential development and commercial milestone payments of up to $83 million on the first three compounds plus 19.9% equity stake and ongoing royaltiesCHARLOTTESVILLE, Va., May 10, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”) a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that Adovate, LLC (formerly known as Ade

  • Zacks

    Is Adial Pharmaceuticals (ADIL) Stock Outpacing Its Medical Peers This Year?

    Here is how Adial Pharmaceuticals, Inc. (ADIL) and Adverum Biotechnologies (ADVM) have performed compared to their sector so far this year.

  • GlobeNewswire

    Adial Pharmaceuticals Reports 2022 Fiscal Year Financial Results and Provides Business Update

    Secured meetings with U.S. and European regulatory agencies Advancing partnership activities in both the U.S. and Europe Ended 2022 fiscal year with cash and cash equivalents of $4.0 million CHARLOTTESVILLE, Va., March 30, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business upda

  • GlobeNewswire

    Adial Pharmaceuticals Engages The Keswick Group to Advance Partnering Activities for the Clinical Development of AD04 for Alcohol Use Disorder

    The Keswick Group is led by experienced pharmaceutical business development executive, Tony GoodmanCHARLOTTESVILLE, Va., March 21, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced it has engaged The Keswick Group, LLC, a biotech strategic commercial and business development advisory fi

  • GlobeNewswire

    Adial Pharmaceuticals to Present at the 35th Annual Roth Conference on March 14th

    CHARLOTTESVILLE, Va., March 08, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that Cary Claiborne, President and Chief Executive Officer of Adial, will be presenting at the 35th Annual Roth Conference being held March 13 - 14, 2023 at The Ritz Carlton, Laguna Niguel located in Dana

  • Benzinga

    Adial Pharma Sees Clear, Cost-Effective Path Toward FDA Approval For Alcohol Use Disorder Candidate

    Adial Pharmaceuticals Inc (NASDAQ: ADIL) shares are trading higher after an update on its regulatory strategy for AD04, the company's lead compound for Alcohol Use Disorder (AUD). The company said additional analysis of ONWARD data identified specific genotypes that outperformed others. The data exhibited AD04 achieved a statistically significant reduction of heavy drinking days in a subgroup of patients - the "heavy drinkers." Adial believes there is a clear, cost-effective path toward FDA appr

  • GlobeNewswire

    Adial Pharmaceuticals Provides Update on Regulatory Strategy for AD04 for Treatment of Alcohol Use Disorder

    Company to pursue path toward U.S. and European approvals; Type C meeting with FDA confirmed for Q2 2023; plans in place to meet with multiple European regulatory authoritiesAdial in discussions with potential pharma partnersConference call to be held at 8:15 a.m. EST tomorrowCHARLOTTESVILLE, Va., March 06, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”) a clinical-stage biopharmaceutical company focused on developing therapies for the treatm

  • GlobeNewswire

    Adial Pharmaceuticals Schedules Business Update Conference Call

    Management to provide an update on its regulatory and partnering strategy for the United States and EuropeCHARLOTTESVILLE, Va., March 02, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will host a conference call and webcast on Tuesday, March 7, 2023, at 8:15 a.m. Eastern Tim

  • Simply Wall St.

    Adial Pharmaceuticals, Inc. (NASDAQ:ADIL): Is Breakeven Near?

    With the business potentially at an important milestone, we thought we'd take a closer look at Adial Pharmaceuticals...

  • GlobeNewswire

    Adial Pharmaceuticals Announces Closing of $0.75 Million At-The-Market Registered Direct Offering

    CHARLOTTESVILLE, Va., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the closing of its previously announced at-the-market registered direct offering of 1,829,269 shares of common stock at a purchase price of $0.41 per share of common stock with a single institutional invest

  • GlobeNewswire

    Adial Pharmaceuticals Announces Pricing of $0.75 Million At-The-Market Registered Direct Offering

    CHARLOTTESVILLE, Va., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase $0.75 million of its common stock in an at-the-market registered direct offering. The purchase price

  • GlobeNewswire

    Adial Pharmaceuticals Confirms Scheduling of Meetings with FDA and European Regulatory Agencies to Advance Clinical Development of AD04 for Alcohol Use Disorder

    Type C meeting with FDA set for Second Quarter Plans in Place to Meet with Multiple Regulatory Agencies Throughout Europe CHARLOTTESVILLE, Va., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it has secured meetings with regulatory authorities in the U.S. and Europe to d

  • GlobeNewswire

    Adial Pharmaceuticals Enters Into Option Agreement for Sale of Purnovate Assets to Adenomed

    Adial to focus on late-stage clinical development for AD04 for alcohol use disorder; potential sale of Purnovate to new company formed by former Adial CEO and current Purnovate CEO, William Stilley Potential development/commercial milestone payments of up to $83 million on first three compounds plus equity stake and ongoing royalties CHARLOTTESVILLE, Va., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”) a clinical-stage biopharmaceuti

  • Zacks

    Adial Pharmaceuticals, Inc. (ADIL) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

    Adial Pharmaceuticals, Inc. (ADIL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

  • GlobeNewswire

    Adial Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

    Advancing submission of AD04 ONWARD™ phase 3 results to regulatory agencies Actively exploring potential partnership opportunities for AD04 and Purnovate compounds Promoted Cary Claiborne to President and Chief Executive Officer CHARLOTTESVILLE, Va., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”) a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disor

  • Zacks

    Forget Bargain Hunting: Play 5 Stocks With Rising P/E

    Bet on these top-ranked stocks with rising P/E to realize outsized gains. Tap Eastside Distilling (EAST), Adial Pharmaceuticals (ADIL), The Buckle (BKE), Ruth's Hospitality Group (RUTH), Insight Enterprises (NSIT).

  • Benzinga

    Adial Pharma Touts Positive Preclinical Data From Chronic Pain Candidate

    Adial Pharmaceuticals Inc's (NASDAQ: ADIL) subsidiary, Purnovate Inc, achieved positive in vivo data for PNV-5030 as a potential treatment for chronic pain. The study was conducted in four groups of ten rats that underwent surgical injury of the sciatic nerve. At 30 minutes post-dose, PNV-5030 reduced pain by 43% compared to the control group, while acetaminophen (APAP) doses did not have a significant effect. PNV-5030 also demonstrated a 49% improvement in pain reduction over acetaminophen. Als

  • GlobeNewswire

    Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate’s PNV-5030 as a Potential Treatment for Chronic Pain

    PNV-5030 significantly reduced pain compared to both placebo and acetaminophen PNV-5030 - Chronic Constrictive Injury Model (Rat) PNV-5030 - Chronic Constrictive Injury Model (Rat) CHARLOTTESVILLE, Va., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today announced that Purnovate, Inc., a subsidiary of Adial focused on developing novel molecules targeting the adenosine receptors for the treatment of major unmet medical needs, achi

  • Benzinga

    Adial Pharma's Subsidiary Shows Encouraging Preclinical Action For Inflammatory Bowel Disease Candidate

    Adial Pharmaceuticals Inc's (NASDAQ: ADIL) subsidiary Purnovate Inc achieved positive in-vivo data from its study with mice treated with Purnovate's PNV-6005 as a potential treatment for inflammatory bowel diseases. PNV-6005 is a selective adenosine 2A receptor agonist designed to have anti-inflammatory properties and protective effects against colitis and other inflammatory bowel diseases. In the study, PNV-6005 demonstrated a statistically significant effect against both primary study endpoint

  • GlobeNewswire

    Adial Pharmaceuticals Announces Positive In-Vivo Non-clinical Data with Purnovate’s PNV-6005 as a Potential Treatment for Ulcerative Colitis

    PNV-6005 significantly reduced both weight loss and colon damage in ulcerative colitis animal model PNV-6005 - DSS-induced Ulcerative Colitis Model (Mice) PNV-6005 - DSS-induced Ulcerative Colitis Model (Mice) CHARLOTTESVILLE, Va., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today announced that Purnovate, Inc., a subsidiary of Adial focused on developing novel molecules targeting the adenosine receptors for the treatment of ma

  • Zacks

    Here's Why Adial Pharmaceuticals, Inc. (ADIL) Could be Great Choice for a Bottom Fisher

    Adial Pharmaceuticals, Inc. (ADIL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

  • Zacks

    Zacks.com featured highlights include Eastside Distilling, Adial Pharmaceuticals, The Buckle, Ruth's Hospitality Group and Insight Enterprises

    Eastside Distilling, Adial Pharmaceuticals, The Buckle, Ruth's Hospitality Group and Insight Enterprises are part of Zacks Screen of the Week article.

  • GlobeNewswire

    Adial Pharmaceuticals Names Cary Claiborne as Chief Executive Officer

    Kevin Schuyler appointed Chairman of Adial’s Board William Stilley moves to post of CEO of Adial’s subsidiary, Purnovate Company to host conference call at 8:30 a.m. EDT tomorrow CHARLOTTESVILLE, Va., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the appointment of Cary J. Claibo